Glenmark Pharmaceuticals announces first in the world launch of its novel, globally-researched, latest-in-class diabetes medicine “Remogliflozin” in Tamil Nadu
Glenmark
Pharmaceuticals today announced the launch of its novel,
patent protected and globally-researched sodium glucose co-transporter (SGLT2) inhibitor
Remogliflozinetabonate (Remogliflozin) in Tamil Nadu
- According ICMR-INDIAB study, prevalence of diabetes in Tamil Nadu is around 10.4%. In South Chennai, the prevalence of diabetes in people under 50 years was more than 20% and over 65% of the known diabetics have uncontrolled sugar values of >200 mg/dl according to a study published in the International Journal of Community Medicine and Public Health
- India is the first country to get access to Remogliflozin, aninnovative, patent-protected sodium glucose co-transporter-2 (SGLT2) inhibitor indicated in the treatment of type-2 diabetes mellitusin adults
- Glenmark’s Remogliflozin is priced over 50% lower than the existing SGLT2 inhibitors in India
Chennai, India; May 15, 2019: Glenmark Pharmaceuticals Ltd (Glenmark), a research-led global integrated pharmaceutical company, today announced the launch of its novel, patent protected and globally-researched sodium glucose co-transporter (SGLT2) inhibitor Remogliflozinetabonate (Remogliflozin) in Tamil Nadu. The drug is indicated in the treatment of type-2 diabetes mellitus in adults.
 |
(L-R) Jason D’Souza, Senior Vice President-Corporate
Communications, Investor Relations,
Corporate Strategy and Alok Malik, Senior
Vice President
- India Formulations, Chronic Cluster |
SGLT2 inhibitors are novel anti-diabetic
drugs that help achieve glycemic control by acting on the SGLT2 receptors in
the proximal convoluted tubule of the kidney, thereby preventing renal
reabsorption of glucose and promoting excretion of glucose in the urine. Along
with providing glycemic control, SGLT2 inhibitors help induce weight loss and
reduce cardiovascular risks.
Glenmark is the first
company in the world to launch Remogliflozinand India is the first country to
get access to this innovative drug. Glenmark has launched Remogliflozin in
Indiaunder brand names “Remo” and “Remozen”. Remogliflozinis the only SGLT2
inhibitor to be manufactured in India from active pharmaceutical ingredient
(API) to formulation.
The company has launched
Remogliflozinat a breakthrough price of Rs. 12.50 per tablet, twice daily,
which is over 50% lower than the existing SGLT2 inhibitors available in
India. Currently, the average per day
therapy cost of SGLT2 inhibitors in India is about Rs. 55. Remogliflozin offers
saving of about Rs. 11,000 per year for diabetes patients on SGLT2 inhibitors.
 |
(L-R) Alok Malik, Senior
Vice President- India Formulations, Chronic Cluster and Jason D’Souza, Senior Vice President-Corporate
Communications, Investor Relations, Corporate Strategy
|
Glenmark received regulatory
approval for Remogliflozinetabonate 100 mg after successfully completing Phase-3
clinical trials in which Remogliflozin demonstrated good efficacy and safety
profile in a head-to-head comparison against Dapagliflozin Remogliflozin has
been studied in 26 clinical trials globally, covering around 2,500 patients
from various ethnicities. Remogliflozin was discovered and developed by
Japanese firm Kissei Pharmaceutical Co. Ltd. and later developed by
GlaxoSmithKline plc and Glenmark collaborator BHV Pharma, a wholly owned
subsidiary of Avolynt, Inc. which is based in North Carolina, USA. Glenmark
secured certain rights to Remogliflozin through a licensing collaboration
agreement with BHV Pharma, and conducted the Phase-3 clinical trial, which
included the largest number of Indian patients tested for any SGLT2 inhibitor.
“Globally, SGLT2
inhibitors are emerging as a preferred treatment for management of type-2
diabetes and Glenmark is proud to introduce an innovative molecule in this
class, which is cutting-edge and researched extensively. Glenmark has been a
pioneer in providing access to the latest treatment options to diabetes
patients in India at a relatively low cost and with the launch of Remogliflozin,
the company aims to increase patients’ access to SGLT2 inhibitors as this class
of drugs have proven benefits for effective diabetes management,” said Alok Malik, Senior Vice President,
India Formulations, Chronic Cluster at Glenmark Pharmaceuticals.
In 2015, Glenmark transformed the
diabetes market by launching its dipeptidyl peptidase-4 (DPP4) inhibitor
Teneligliptin at a price that was approximately 55% lower than the other DPP4
inhibitors available in India at that time. Since then, the access to DPP4
inhibitors has increased significantly and currently more than 100 brands of
Teneligliptin from several companies are available in the country.
India is estimated to have around 72
million adults living with diabetes, according to the International Diabetes Federation’s
Diabetes Atlas 2017.1According
to Indian Council of Medical Research’s (ICMR) – INDIAB study on prevalence of
diabetes and pre-diabetes published in the Lancet Diabetes Endocrinology 2017,
the prevalence of diabetes in Tamil Nadu was around 10.4%.2In
October 2018, the International Journal of Community Medicine and Public Health
published a study involving 1361 subjects on prevalence of undiagnosed and
uncontrolled diabetes mellitus among adults in South Chennai. According to this
study, nearly 22% of the subjects were known diabetics and 10.3% were newly
diagnosed diabetics. It also revealed that over 65% of the known diabetics had
uncontrolled sugar values of >200 mg/dl and the prevalence of diabetes in
people under 50 years was more than 20%.3
According to data from
IQVIA, India’s diabetes market is estimated at 11,413 crore as of MAT March
2019.The market size of SGLT2 inhibitors is estimated at 574 crore as of MAT
March 2019.
About Glenmark
Pharmaceuticals
Glenmark Pharmaceuticals Ltd. (GPL) is a
research-driven, global, integrated pharmaceutical organization. It is ranked
among the top 75 Pharma& Biotech companies of the world in terms of revenue
(SCRIP 100 Rankings published in the year 2018). Glenmark is a leading player
in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new
biological entity). Glenmark has several molecules in various stages of
clinical development and is focused in the areas of oncology, dermatology and
respiratory.
The company has a significant presence in
the branded generics markets across emerging economies including India.
Glenmark has 16 manufacturing facilities across five countries and has six
R&D centers. The Generics business of Glenmark services the requirements of
the US and Western European markets. The API business sells its products in
over 80 countries, including the US, various countries in the EU, South America
and India.
Reference:
IDF Diabetes Atlas 2017
.jpg)
.jpg)